#OHDSI2021 Symposium Preview

OHDSI Community Call
August 10, 2021 • 11 am ET

Upcoming OHDSI Community Calls

Date	Topic
August 10	2021 Global Symposium Preview
August 17	New Developments In OHDSI
August 24	Back to School
August 31	NO MEETING
September 7	Final Symposium Updates and Logistics
September 14	OHDSI Symposium
September 21	Welcome to OHDSI
September 28	Breakout Sessions (Collaboration Opportunities)

Three Stages of The Journey

Where Have We Been?

Where Are We Now?

Where Are We Going?

Inaugural OHDSI/HL7 Meeting

The inaugural open HL7-OHDSI meeting took place last week.

OHDSI
OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS

This meeting goal was to review and update plans for the collaboration, and discuss how members of the community can get involved. OHDSI Speakers included George Hripcsak, Christian Reich, and Jon Duke.

HL7 International

August OHDSI Newsletter Available

Community Updates

Where Have We Been

• Two types of drugs that are recommended as a first treatment for patients with high blood pressure were found equally effective in improving cardiovascular outcomes, though the more popular type causes slightly more side effects, finds a multinational observational study led by the OHDSI community.

• The CHARYBDIS Project produced two newly published studies in July, focusing on COVID-19 impact around both obesity and cancer.

• More than 30 OHDSI collaborators joined the HADES Unit-Test-A-Thon (July 14-16) to increase the reliability of our open-source R packages that facilitate almost all community studies. Prior to the event, only six of the 20 tools had at least 80% coverage; by the end, 17 tools reached that mark.

Where We Are

• The inaugural meeting in the OHDSI/HL7 collaboration will be held Wednesday, August 4 at 10 am ET. A list of speakers is available, and you can register for this meeting now.

• Several new workgroups have been introduced throughout the summer, including the Education WG, the Early-Stage Researchers WG, the Health Equity WG, and the Africa Chapter. New collaborators are welcome in each of these workgroups, as well as the more established ones. You can join these efforts by filling out this form.

Where We Are Going

• Registration is OPEN for the 2021 Global Symposium, which will take place Sept. 12-15 in a virtual environment. The collaborator showcase will be held on both Sept. 14 and 15. We received a record number of showcase submissions, and accepted presentations will be notified around August 2.

OHDSI

The Journey Newsletter (August 2021)

From collaborative work on our open-source tool packages to the latest publications from our open-science network, July was another busy month for the OHDSI community. Please check out all the details in the latest edition of our official newsletter. #JoinTheJourney

July Publications

Gaudet-Blavignac C, Raisaro JL, Touré V, Österle S, Crameri K, Lovis C. A National, Semantic-Driven, Three-Pillar Strategy to Enable Health Data Secondary Usage Interoperability for Research Within the Swiss Personalized Health Network: Methodological Study. JMIR Med Inform 2021;9(6):e27591. doi: 10.2196/27591

João Rafael Almeida, João Figueira Silva, Sérgio Matos, José Luís Oliveira. A two-stage workflow to extract and harmonize drug mentions from clinical notes into observational database. Journal of Biomedical Informatics, Volume 120, 2021, 103849, ISSN 1532-0464, doi.org/10.1016/j.jbi.2021.103849.

Roel E, Pistillo A, Recalde M, Sena AG, Fernandez-Bertolin S, Aragon M, Puente D, Ahmed WU, Alghoul H, Alser O, Alshammari TM, Areia C, Blacketer C, Carter W, Casajust P, Culhane AC, Dawoud D, DeFalco F, DuVall SL, Falconer T, Golozar A, Gong M, Hester L, Hripcsak G, Tan EH, Jeon H, Jonnagaddala J, Lai LY, Lynch KE, Matheny ME, Morales DR, Natarajan K, Nyberg F, Ostropolets A, Posada JD, Prats-Uribe A, Reich CG, Rivera DR, Schilling LM, Soerjomataram I, Shah K, Shah NH, Shen Y, Spotnitz M, Subbian V, Suchard MA, Trama A, Zhang L, Zhang Y, Ryan PB, Prieto-Alhambra D, Kostka K, Duarte-Salles T. Characteristics and outcomes of over 300,000 COVID-19 individuals with history of cancer in the United States and Spain. Cancer Epidemiol Biomarkers Prev July 16 2021 DOI: 10.1158/1055-9965.EPI-21-0266.

Recalde M, Roel E, Pistillo A, Sena AG, Prats-Uribe A, Ahmed WU, Alghoul H, Alshammari TM, Alser O, Areia C, Burn E, Casajust P, Dawoud D, DuVall SL, Falconer T, Fernández-Bertolín S, Golozar A, Gong M, Lai LYH, Lane JCE, Lynch KE, Matheny ME, Mehta PP, Morales DR, Natarjan K, Nyberg F, Posada JD, Reich CG, Rijnbeek PR, Schilling LM, Shah K, Shah NH, Subbian V, Zhang L, Zhu H, Ryan P, Prieto-Alhambra D, Kostka K, Duarte-Salles T. Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom. Int J Obes (Lond). 2021 Jul 15. doi: 10.1038/s41366-021-00893-4.

RuiJun Chen, Marc A. Suchard, Harlan M. Krumholz, Martijn J. Schuemie, Steven Shea, Jon Duke, Nicole Pratt, Christian G. Reich, David Madigan, Seng Chan You, Patrick B. Ryan, George Hripcsak. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. Hypertension. 26 Jul 2021 https://doi.org/10.1161/HYPERTENSIONAHA.120.16667

August Newsletter

Among Effective Antihypertensive Drugs, Less Popular Choice Is Slightly Safer

Hypertension

ORIGINAL ARTICLE

Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers

A Multinational Cohort Study

RuiJun Chen, Marc A. Suchard, Harlan M. Krumholz, Martijn J. Schuemie, Steven Shea, Jon Duke, Nicole Pratt, Christian G. Reich, David Madigan, Seng Chan You, Patrick B. Ryan, George Hripcsak

ABSTRACT: ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers (ARBs) are equally guideline-recommended first-line treatments for hypertension, yet few head-to-head studies exist. We compared the real-world effectiveness and safety of ACE inhibitors versus ARBs in the first-line treatment of hypertension. We implemented a retrospective, new-user comparative cohort design to estimate hazard ratios using techniques to minimize residual confounding and bias, specifically large-scale propensity score adjustment, empirical calibration, and full transparency. We included all patients with hypertension initiating monotherapy with an ACE inhibitor or ARB between 2006 and 2018 across 8 databases from the United States, Germany, and South Korea. The primary outcomes were acute myocardial infarction, heart failure, stroke, and composite cardiovascular events. We also studied 51 secondary and safety outcomes including angioedema, cough, syncope, and electrolyte abnormalities. Across 8 databases, we identified 2 297 881 patients initiating treatment with ACE inhibitors and 673 938 patients with ARBs. We found no statistically significant difference in the primary outcomes of acute myocardial infarction (hazard ratio, 1.11 for ACE versus ARB [95% CI, 0.95–1.30]), heart failure (hazard ratio, 1.03 [0.87–1.24]), stroke (hazard ratio, 1.07 [0.91–1.27]), or composite cardiovascular events (hazard ratio, 1.06 [0.90–1.25]). Across secondary and safety outcomes, patients on ARBs had significantly lower risk of angioedema, cough, pancreatitis, and GI bleeding. In our large-scale, observational network study, ARBs do not differ statistically significantly in effectiveness at the class level compared with ACE inhibitors as first-line treatment for hypertension but present a better safety profile. These findings support preferentially prescribing ARBs over ACE inhibitors when initiating treatment for hypertension. (*Hypertension*. 2021;78:00–00. DOI: 10.1161/HYPERTENSIONAHA.120.16667.) • Data Supplement

Key Words: angiotensin receptor blocker ■ angiotensin receptor ■ cardiovascular outcomes ■ hypertension ■ safety

Two types of drugs that are recommended as a first treatment for patients with high blood pressure were found equally effective in improving cardiovascular outcomes, though the more popular type causes slightly more side effects, finds a multinational observational study led by researchers within the Observational Health Data Sciences and Informatics (OHDSI) community.

The study, which analyzed claims and electronic health data from millions of patients worldwide, is the largest to compare the safety and efficacy of ACE inhibitors and ARBs, two commonly prescribed antihypertensive drugs. It was published online in Hypertension on July 26, 2021.

Read The Study

OHDSI Press Release

OHDSI Shoutouts!



Any shoutouts from the community? Please share and help promote and celebrate OHDSI work!

Have a study published? Please send to sachson@ohdsi.org so we can share during this call and on our social channels.
Let's work together to promote the collaborative work happening in OHDSI!

Three Stages of The Journey

Where Have We Been?

Where Are We Now?

Where Are We Going?

Upcoming Workgroup Calls

Date	Time (ET)	Meeting
Tuesday	2 pm	Health Equity
Wednesday	8 am	Vaccine Vocabulary
Wednesday	10 am	OMOP CDM Oncology – Development Subgroup
Wednesday	2 pm	Natural Language Processing
Thursday	1 pm	OMOP CDM Oncology – CDM/Vocabulary Subgroup
Friday	1 pm	Phenotype Development and Evaluation
Friday	11 pm	China Chapter
Monday	10 am	GIS-Geographic Information System
Tuesday	9 am	OMOP CDM Oncology – Genomic Subgroup

www.ohdsi.org/upcoming-working-group-calls

OHDSI APAC Call Tonight

Due to the ETL Training taking place this Wednesday and Thursday, the APAC Community Call has been moved to **tonight at 11 pm ET**.

This call will be a replay of today's Symposium preview.

Get Access To Different Teams/WGs/Chapters

5. Select the workgroups you want to join (you can refer to the WIKI for work group objectives www.ohdsi.org/web/wiki/doku.php?id=projects:overview)

- [ ] ATLAS
- [ ] Clinical Trials
- [ ] Common Data Model
- [ ] Data Quality Dashboard Development
- [ ] Early-stage Researchers
- [ ] Education Work Group
- [ ] Electronic Health Record (EHR) ETL
- [ ] Geographic Information System (GIS)
- [ ] HADES Health Analytics Data-to-Evidence Suite
- [ ] Health Equity
- [ ] Latin America
- [ ] Medical Devices
- [ ] Natural Language Processing
- [ ] OHDSI APAC
- [ ] OHDSI APAC Steering Committee
- [ ] OHDSI Steering Committee
- [ ] Oncology
- [ ] Patient-Generated Health Data
- [ ] Pharmacovigiliance Evidence Investigation
- [ ] Phenotype Development and Evaluation
- [ ] Population-Level Effect Estimation / Patient-Level Prediction
- [ ] Psychiatry
- [ ] Registry (formerly UK Biobank)
- [ ] Surgery and Perioperative Medicine
- [ ] Vaccine Safety
- [ ] Vaccine Vocabulary
- [ ] Women of OHDSI

6. Select the chapter(s) you want to join

- [ ] Australia
- [ ] China
- [ ] Europe
- [ ] Japan
- [ ] Korea
- [ ] Singapore
- [ ] Taiwan

7. Select the studies you want to join

- [ ] HERA-Health Equity Research Assessment
- [ ] PIONEER for Prostate Cancer (study-a-thon ended)
- [ ] SCYLLA (SARS-Cov-2 Large-scale Longitudinal Analyses)

Get Access To Different Teams/WGs/Chapters



5. Select the workgroups you want to join (you can refer to the WIKI for work group objectives www.ohdsi.org/web/wiki/doku.php?id=projects:overview)

- [ ] ATLAS
- [ ] Clinical Trials
- [ ] Common Data Model
- [ ] Data Quality Dashboard Development
- [ ] Early-stage Researchers
- [ ] Education Work Group
- [ ] Electronic Health Record (EHR) ETL
- [ ] Geographic Information System (GIS)
- [ ] HADES Health Analytics Data-to-Evidence Suite
- [ ] Health Equity
- [ ] Latin America
- [ ] Medical Devices
- [ ] Natural Language Processing
- [ ] OHDSI APAC
- [ ] OHDSI APAC Steering Committee
- [ ] OHDSI Steering Committee
- [ ] Oncology
- [ ] Patient-Generated Health Data
- [ ] Pharmacovigiliance Evidence Investigation
- [ ] Phenotype Development and Evaluation
- [ ] Population-Level Effect Estimation / Patient-Level Prediction
- [ ] Psychiatry
- [ ] Registry (formerly UK Biobank)
- [ ] Surgery and Perioperative Medicine
- [ ] Vaccine Safety
- [ ] Vaccine Vocabulary
- [ ] Women of OHDSI

6. Select the chapter(s) you want to join

- [ ] Australia
- [ ] China
- [ ] Europe
- [ ] Japan
- [ ] Korea
- [ ] Singapore
- [ ] Taiwan

7. Select the studies you want to join

- [ ] HERA-Health Equity Research Assessment
- [ ] PIONEER for Prostate Cancer (study-a-thon ended)
- [ ] SCYLLA (SARS-Cov-2 Large-scale Longitudinal Analyses)

CDM Hack-A-Thon

The CDM Working Group will be holding a Hack-a-Thon on August 18-19.

In preparation for the symposium they will be readying CDM v5.4 by writing both R code and documentation of the model. No matter your skill-level you are welcome to join!



Next CBER Best Seminar

The next edition of the CBER BEST Initiative Seminar Series will be **Sept. 8 at 11 am ET. Robert Platt** (McGill University) will present a talk on "**COVID-19 pharmacoepidemiology in Canada**."

You can register for this talk by using the link below.

Date: September 8, 2021

Time: 11:00 -12:00 PM ET

Topic: COVID-19 pharmacoepidemiology in Canada

Background: The CBER BEST Initiative Seminar Series is designed to share and discuss recent research of relevance to ongoing and future surveillance activities of CBER regulated products, namely biologics. The series focuses on safety and effectiveness of biologics including vaccines, blood components, blood-derived products, tissues and advanced therapies. The seminars will provide information on characteristics of biologics, required infrastructure, study designs, and analytic methods utilized for pharmacovigilance and pharmacoepidemiologic studies of biologics. They will also cover information regarding potential data sources, informatics challenges and requirements, utilization of real-world data and evidence, and risk-benefit analysis for biologic products. The length of each session may vary, and the presenters will be invited from outside FDA. Please see the details below for our upcoming seminar. Anyone can register and join for free. Stay tuned for more details and additional webinars during the year.

Description: The Canadian Network for Observational Drug Effect Studies (CNODES) is mandated by Health Canada to conduct studies on drug utilization, safety, and effectiveness CNODES is currently engaged in several Health Canada-assigned studies of potential treatments for COVID-19 and of COVID-related side-effects of commonly used medications, including some requested by international regulators. Finally, CNODES is providing methodological support to proposed studies of COVID-19 vaccine safety and effectiveness in Canada. I will review this work, and some of the challenges specific to observational studies of drug and vaccine safety in the Canadian setting.

Presenter: Robert Platt, PhD

Robert Platt is Professor in the departments of Pediatrics and of Epidemiology, Biostatistics, and Occupational Health (EBOH) at McGill University. He is a Senior Investigator at the Research Institute of the McGill University Health Centre and the Lady Davis Institute of the Jewish General Hospital, and Investigator at the McGill Pharmacoepidemiology Research Unit, and holds the Albert Boehringer I endowed chair in Pharmacoepidemiology. Dr. Platt is the Executive Co-Lead and leader of the Methods team of the Canadian Network for Observational Drug Effect Studies (CNODES). His research focuses on improving methods for the study of medications using administrative data, with an emphasis on methods for causal inference and a substantive focus on medications in pregnancy. Dr. Platt is on editor-in-chief of Statistics in Medicine and is on the editorial boards of the American Journal of Epidemiology and Pharmacoepidemiology and Drug Safety. He has published over 325 articles, one book and several book chapters on biostatistics and epidemiology.

Registration: https://northeastern.zoom.us/webinar/register/WN_pAyY6-I2SU6MHFU2mnMtEA

Register Here

Titan Award Nominations are OPEN!

The **2021 Titan Award** nominations are now open! The OHDSI Titan Awards serve to recognize those who have gone above and beyond to foster community engagement, lead research and development efforts and make significant contributions towards OHDSI's mission.

The nomination deadline is Aug. 30 at 5 pm ET. Please use the link below to honor deserving members of our community!



Nominate Here

2021 Global Symposium: Sept. 12-15

2021 Global OHDSI Symposium

We are excited to announce that general registration for the 2021 Global OHDSI Symposium, which will be held virtually in Microsoft Teams, Sept. 12-15, is now open! This will be our seventh annual OHDSI Symposium, and it will provide another opportunity for our community to come together, share ideas, learn from each other and network with our fellow collaborators.

We are working on many details for the four-day event, which will feature plenary talks, a state of the community presentation and our collaborator showcase. One detail has not changed — the symposium remains free to attend and is open to anybody, whether you are a community veteran or a newcomer looking to learn more about how we generate real-world evidence that promotes better health decisions and better care.

Please continue to check the OHDSI website (www.ohdsi.org) and the OHDSI social platforms periodically for updates as we plan for a rewarding, online event!

What Can You Expect At #OHDSI2021?

The 2021 Global OHDSI Symposium will be held virtually for the second straight year. This allows both veteran collaborators and those new to OHDSI from around the world to come together and share ideas, learn from each other and enjoy the spirit of our community. If you missed our 2020 Global Symposium, check out the link below to get a sense of what takes place during our biggest event of the year.

The 2020 Global Symposium

While we are excited to again create an opportunity for everyone to participate in the Symposium for free if they choose, there are costs associated with coordinating all OHDSI community activities. To help offset these costs, we provide the additional optional opportunity for participants to support the OHDSI community through 'registration contribution' and 'optional registration fee' tickets. Thank you in advance for your generous support! **Should you require a tax receipt for your contribution, please email symposium@ohdsi.org BEFORE you make the contribution through the Eventbrite registration site.**

In addition, as all OHDSI activities depend largely on government grants and organization sponsorships, please email symposium@ohdsi.org if you would like to consider sponsorship opportunities for this year's symposium.

Should you wish to change or cancel your registration ticket, kindly log into your Eventbrite account where you may edit or cancel your free registration ticket at any time. Registration contribution tickets/optional registration fee tickets are non-refundable; however, if you need to make changes to this ticket, kindly email us at symposium@ohdsi.org. Also, if you make any changes to your registration ticket such as a name change or update an email address, please email us at symposium@ohdsi.org to inform us as well. Thank you!

To Register for the 2021 Global OHDSI Symposium, please click the button below:

Register For #OHDSI2021 Here!

Symposium Information and Registration

Where Are We Going?

Any other announcements of upcoming work, events, deadlines, etc?

Three Stages of The Journey

Where Have We Been?

Where Are We Now?

Where Are We Going?

August 3 Community Call: APAC Regional Updates

Australia
Roger Ward

Japan
Tatsuo Hiramatsu



South Korea
Seng Chan You

China
Hua Xu

Singapore
Mengling 'Mornin' Feng

Taiwan
Jason Hsu